Conference Details - Overview
View all Conferences
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Oncology Best Practices: Advances in Breast Cancer
John Bentley's Restaurant
Palo Alto, CA
July 29, 2008
Conference Overview
The purpose of this meeting is to discuss strategies for patients with early-stage, advanced, or metastatic breast cancer, including optimizing the use of chemotherapy, integrating novel targeted agents into treatment, and managing treatment-related adverse effects. The relevance of data reported at recent international oncology conferences to physician practice will also be discussed. This educational program is directed toward medical oncologists interested in reviewing the most recent clinical trial data on the treatment of breast cancer. Surgical and radiation oncologists and other health professionals interested in the treatment of breast cancer are also invited to attend.At the conclusion of this meeting, you should be able to:
- Evaluate recent results from adjuvant endocrine trials and related substudies
- Review data regarding the efficacy and toxicity of anthracycline-, taxane-, and antimetabolite-based regimens, including both conventional and novel formulations as well as novel cytotoxic agents, in the treatment of breast cancer
- Assess strategies for ameliorating treatment-related adverse events
- Discuss antibodies and small-molecule tyrosine kinase inhibitors targeting HER2 and their integration into current treatment algorithms
- Evaluate novel agents targeting the angiogenesis pathway and their integration into current treatment regimens for breast cancer
- Apply results from clinical trials to common case scenarios
- Discuss controversial treatment issues in the management of patients with breast cancer
Educational Grants
An educational grant for this activity was provided by:
- Bristol-Myers Squibb
- GlaxoSmithKline